Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (ImbruVeRCHOP)

The ImbruVeRCHOP-Trials is an Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial to evaluate the efficacy and feasibility of Ibrutinib and Bortezomib in the

renal function
tositumomab
platelet count
doxorubicin
vincristine
  • 4 views
  • 28 Jan, 2022
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

daratumumab to increase efficacy and improve outcomes of patients in both the relapse refractory and newly diagnosed settings. Two large Phase 2 trails using lenalidomide and dexamethasone or bortezomib and

bone marrow procedure
bortezomib
daratumumab
melphalan
monoclonal antibodies
  • 15 views
  • 24 Jan, 2021
  • 2 locations
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (Generate-Boost)

will be specifically targeted by a substance called bortezomib. The trial addresses patients with severe autoimmune encephalitis. The aim of the trial is to evaluate the efficacy and safety of

  • 5 views
  • 14 Mar, 2022
  • 2 locations
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can

  • 0 views
  • 02 Jan, 2022
  • 1 location
Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

(500mg) combined with bortezomib (1.3mg/m2 twice a week for two weeks). The treatment course would be repeated three months later.

treatment regimen
prednisone
  • 8 views
  • 21 Oct, 2021
  • 1 location
Bortezomib Isatuximab Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients

This is a single-arm, open-label phase II study with a safety lead-in phase.

cell transplantation
dexamethasone
bone marrow procedure
hypercalcemia
anemia
  • 0 views
  • 21 Nov, 2021
  • 1 location
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma

  • 0 views
  • 15 Dec, 2021
  • 1 location
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Bortezomib to the relapsing regimen improves the proportion of second complete remissions without increasing chemotherapy toxicity. Therefore, proteasome inhibitors can drastically modify the prognosis of

  • 0 views
  • 24 Mar, 2022
  • 1 location
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)

An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly

bone marrow procedure
bortezomib
measurable disease
chemotherapy regimen
platelet count
  • 0 views
  • 10 May, 2022
  • 1 location
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

own to treat some blood cell cancers. Objectives To test the safety and efficacy of the drug combination of bortezomib and clofarabine.

bortezomib
cancer
chemotherapy regimen
bisphosphonate
solid tumour
  • 25 views
  • 18 May, 2022
  • 1 location